Promotional Communication. The medical devices SUDOSCAN & EZSCAN are regulated health products under the CE certification, Class IIa, according to the European Medical Device directive – SGS Belgium, notified body 1639. The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 2021/01/12
SUDOSCAN IN ONCOLOGY
SUDOSCAN has demonstrated its efficacy in the field of oncology
Peripheral neuropathy is the result of damage to peripheral nerves, including small fiber neuropathy involving small and myelinated nerves (Aδ), as well as unmyelinated nerves (unmyelinated C fibers). In peripheral neuropathy, small somatic and autonomic fibers can be affected. Small fibers control thermal perception, pain perception, and autonomic functions such as cardiac, pulmonary or enteric functions .
Peripheral neuropathy can be a complication of several diseases such as diabetes, neurological or metabolic disorders, and infections. It can also result from certain drugs such as chemotherapy or alcohol consumption.
This complication can occur in the very early stages of disease. Its detection may help physicians to better manage their patients and avoid advanced complications.
In the field of oncology, SUDOSCAN has demonstrated its clinical utility to detect chemotherapy induced polyneuropathy (CIPN). This can help the physician to manage treatment and limit neuropathy worsening, thus improving the quality of life of the patients receiving chemotherapy or in palliative care.
Detection of painful oxaliplatin-induced peripheral neuropathy can be easily performed with SUDOSCAN to help treatment management 
Oxaliplatin-induced peripheral neuropathy (OIPN) has been assessed using SUDOSCAN in a study conducted by Delmotte et al from Saint Joseph Hospital, Paris. The aim of the prospective study was to investigate how Electrochemical Skin Conductance (ESC, measured with SUDOSCAN) could be helpful in diagnosing OIPN.
36 patients with cancer, treated for at least three months with oxaliplatin, and suffering from clinical OIPN were included. Low ESC measurements signal decreased sudomotor nerve function, while a Neuropathic Pain Symptom Inventory (NPSI) score > 0 indicates painful symptoms. The main result was the correlation between the NPSI score and ESC scores in the hands (rho value = -0.69, p < 0.0001) and feet (rho value = -0.79, p < 0.0001). ESC values were lower in neuropathic patients with painful symptoms than in those without painful symptoms (p = 0.0003 and p < 0.0001 for hands and feet, respectively).
These preliminary data suggest that ESC measured with SUDOSCAN could be a useful objective marker of painful oxaliplatin-induced neuropathy and could complement the use of subjective clinical scales.
ESC values measured on hands and feet according to the presence or absence of a painful neuropathy.
SUDOSCAN is a quick and non-invasive test that provides an accurate evaluation of sweat gland function reflecting the status of the autonomic nervous system. With quantitative and reproducible results, SUDOSCAN allows physicians to detect early and follow-up peripheral neuropathy to monitor disease progression and assess treatment efficacy for better patient management. SUDOSCAN efficacy has been evaluated in the assessment of small fiber neuropathies in several diseases and compared to reference tests recommended in guidelines.
 Levine TD. Small Fiber Neuropathy: Disease Classification Beyond Pain and Burning. J Cent Nerv Syst Dis. 2018;10:1179573518771703. Published 2018 Apr 18.
 Delmotte J.B et al. Electrochemical Skin Conductance as a Marker of Painful Oxaliplatin-Induced Peripheral Neuropathy. Neurol Res Int. 2018; 2018: 1254602.